Long-term Follow-up (LTFU) of Participants Who Received Azer-Cel
Starting soon
Conditions studied: B-cell Mediated Autoimmune Disorders
In brief
The main objective of this study is to collect data on the long-term safety of azer-cel, primarily through the capture of clinical events of interest (CEI) for up to 15 years following participation in TG-Azercel -101 study.
Key facts
- Study ID
- NCT07577583
- Run by
- TG Therapeutics, Inc.
- People needed
- 32
- Starts
- 2027-05-01
- Expected to finish
- 2039-12-01
- Last updated by the study team
- 2026-05-11
Who can join
Age: 18 and older, up to 62. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Received at least 1 dose of azer-cel in TG-Azercel -101 study.
- Signed informed consent form (ICF).
- Willingness and ability to adhere to the study schedule and all other protocol requirements.
- Exclusion Citeria:
- No unique exclusion criteria apply to this study.
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.